Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.
The partners will evaluate several quality control assays for genome editing research, eventually creating a protocol for analyzing mutations in genomic DNA.
The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US.
LGC said it plans to use Douglas Scientific's PCR and qPCR platforms to provide customers with enhanced high-throughput genotyping and qPCR instruments.
The two companies will use KeyGene's technology for the genetic analysis of field and vegetable crops.
The investment firm says it will acquire LGC for an undisclosed amount.
LGC will offer TraitGenetics' SNP genotyping services using Illumina and Affymetrix array technologies to its global customers.
The three-year deal includes more than 100,000 pre-designed assays for public domain human SNPs.
Registered users of the IBP will have access to a range of genotyping services through LGS.
The acquisition will enable LGC to deliver product and laboratory service offerings for core qPCR and end-point PCR applications, as well as NGS.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.